<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35114419</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1810</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>244</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Translational research : the journal of laboratory and clinical medicine</Title>
          <ISOAbbreviation>Transl Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In Vivo Cardiac-specific Expression of Adenylyl Cyclase 4 Gene Protects against Klotho Deficiency-induced Heart Failure.</ArticleTitle>
        <Pagination>
          <StartPage>101</StartPage>
          <EndPage>113</EndPage>
          <MedlinePgn>101-113</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.trsl.2022.01.006</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1931-5244(22)00019-6</ELocationID>
        <Abstract>
          <AbstractText>Klotho is an aging-suppressor gene. Klotho gene deficiency causes heart failure in Klotho-hypomorphic mutant (KL (-/-)) mice. RNA-seq and western blot analysis showed that adenylyl cyclase type IV (AC4) mRNA and protein expression was largely decreased in cardiomyocytes of KL (-/-) mice. The objective of this study was to investigate whether in vivo cardiac-specific expression of AC4 gene protects against Klotho deficiency-induced heart failure. Interestingly, in vivo AAV-based cardiac-specific AC4 gene expression increased left ventricular fractional shortening, ejection fraction, stroke volume, and left ventricular end-diastolic volume in KL (-/-) mice, suggesting that cardiac-specific AC4 gene expression improves Klotho deficiency-induced heart dysfunction. Cardiac-specific AC4 gene expression also decreased Klotho deficiency-induced cardiac hypertrophy. Cardiac-specific AC4 gene expression alleviated Klotho deficiency-induced cardiac fibrosis and calcification. Furthermore, cardiac-specific AC4 gene expression attenuated mitochondrial dysfunction, superoxide accumulation and cardiomyocyte apoptotic cell death. Thus, downregulation of AC4 may contribute to Klotho deficiency-induced heart failure. Mechanistically, AAV2/9-αMHC-AC4 increased cardiomyocytic cAMP levels and thus regulated the PKA-PLN-SERCA2 signal pathway, which is critical in modulating calcium flux and mitochondrial function. In conclusion, cardiac-specific AC4 gene expression protects against Klotho deficiency-induced heart failure through increasing cardiomyocytic cAMP levels, which alleviates cAMP-dependent mitochondrial dysfunction, superoxide accumulation and apoptotic cell death. AC4 regulates superoxide levels via the cAMP-PKA pathway. AC4 could be a potential therapeutic target for heart failure associated with Klotho deficiency. Heart failure is the major cause of mortality in patients with chronic kidney disease (CKD). A decrease in Klotho levels is linked to CKD.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Kai</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America; Department of Physiology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Shirley</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America; Department of Physiology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Zhongjie</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America; Department of Physiology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America. Electronic address: Zsun10@uthsc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AG049780</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL118558</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL154147</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL122166</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG062375</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Transl Res</MedlineTA>
        <NlmUniqueID>101280339</NlmUniqueID>
        <ISSNLinking>1878-1810</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>11062-77-4</RegistryNumber>
          <NameOfSubstance UI="D013481">Superoxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.2.1.31</RegistryNumber>
          <NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.2.1.31</RegistryNumber>
          <NameOfSubstance UI="D000090265">Klotho Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.6.1.1</RegistryNumber>
          <NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.6.1.1</RegistryNumber>
          <NameOfSubstance UI="C406262">adenylyl cyclase 4</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006332" MajorTopicYN="N">Cardiomegaly</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090265" MajorTopicYN="N">Klotho Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013481" MajorTopicYN="N">Superoxides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflict of Interest. None. All authors have read the journal’s policy on disclosure of potential conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>20</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35114419</ArticleId>
        <ArticleId IdType="mid">NIHMS1778221</ArticleId>
        <ArticleId IdType="pmc">PMC9119924</ArticleId>
        <ArticleId IdType="doi">10.1016/j.trsl.2022.01.006</ArticleId>
        <ArticleId IdType="pii">S1931-5244(22)00019-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al.
Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143:e254–e743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33501848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Liu D, Varin A, Nicolas V, Courilleau D, Mateo P, et al.
A cardiac mitochondrial cAMP signaling pathway regulates calcium accumulation, permeability transition and cell death. Cell death &amp; disease. 2016;7:e2198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4855650</ArticleId>
            <ArticleId IdType="pubmed">27100892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qasim H, McConnell BK. AKAP12 Signaling Complex: Impacts of Compartmentalizing cAMP-Dependent Signaling Pathways in the Heart and Various Signaling Systems. J Am Heart Assoc. 2020;9:e016615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7670535</ArticleId>
            <ArticleId IdType="pubmed">32573313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fenske S, Hennis K, Rötzer RD, Brox VF, Becirovic E, Scharr A, et al.
cAMP-dependent regulation of HCN4 controls the tonic entrainment process in sinoatrial node pacemaker cells. Nature communications. 2020;11:5555.</Citation>
        </Reference>
        <Reference>
          <Citation>Feldman AM. Adenylyl cyclase: a new target for heart failure therapeutics. Circulation. 2002;105:1876–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11997269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwatsubo K, Bravo C, Uechi M, Baljinnyam E, Nakamura T, Umemura M, et al.
Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase. Am J Physiol Heart Circ Physiol. 2012;302:H2622–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3378263</ArticleId>
            <ArticleId IdType="pubmed">22505646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai NC, Tang T, Gao MH, Saito M, Takahashi T, Roth DM, et al.
Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice. J Am Coll Cardiol. 2008;51:1490–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3095112</ArticleId>
            <ArticleId IdType="pubmed">18402905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z, Babu GJ, Wen H, Fefelova N, Gordan R, Sui X, et al.
Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heart. American journal of physiology Heart and circulatory physiology. 2015;308:H240–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4312946</ArticleId>
            <ArticleId IdType="pubmed">25485900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Hof T, Baldwin TA, Chen L, Kass RS, Dessauer CW. Regulation of I(Ks) Potassium Current by Isoproterenol in Adult Cardiomyocytes Requires Type 9 Adenylyl Cyclase. Cells. 2019;8.</Citation>
        </Reference>
        <Reference>
          <Citation>Mewes M, Lenders M, Stappers F, Scharnetzki D, Nedele J, Fels J, et al.
Soluble adenylyl cyclase (sAC) regulates calcium signaling in the vascular endothelium. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019;33:13762–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31585052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinboelting S, Diaz A, Moniot S, van den Heuvel J, Weyand M, Levin LR, et al.
Crystal structures of human soluble adenylyl cyclase reveal mechanisms of catalysis and of its activation through bicarbonate. Proc Natl Acad Sci U S A. 2014;111:3727–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3956179</ArticleId>
            <ArticleId IdType="pubmed">24567411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phan HM, Gao MH, Lai NC, Tang T, Hammond HK. New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy. Trends Cardiovasc Med. 2007;17:215–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2278010</ArticleId>
            <ArticleId IdType="pubmed">17936202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al.
Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9363890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al.
Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2536606</ArticleId>
            <ArticleId IdType="pubmed">16123266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D, et al.
Life extension factor klotho enhances cognition. Cell reports. 2014;7:1065–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4176932</ArticleId>
            <ArticleId IdType="pubmed">24813892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T, Sasaki T, et al.
Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:2331–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1892974</ArticleId>
            <ArticleId IdType="pubmed">17287345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen K, Wang S, Sun QW, Zhang B, Ullah M, Sun Z. Klotho Deficiency Causes Heart Aging via Impairing the Nrf2-GR Pathway. Circ Res. 2021;128:492–507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8782577</ArticleId>
            <ArticleId IdType="pubmed">33334122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varshney R, Ali Q, Wu C, Sun Z. Monocrotaline-Induced Pulmonary Hypertension Involves Downregulation of Antiaging Protein Klotho and eNOS Activity. Hypertension. 2016;68:1255–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5063703</ArticleId>
            <ArticleId IdType="pubmed">27672025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, et al.
Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22:124–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3014041</ArticleId>
            <ArticleId IdType="pubmed">21115613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y, Sun Z. Antiaging Gene Klotho Attenuates Pancreatic beta-Cell Apoptosis in Type 1 Diabetes. Diabetes. 2015;64:4298–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4657580</ArticleId>
            <ArticleId IdType="pubmed">26340932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y, Sun Z. In vivo pancreatic beta-cell-specific expression of antiaging gene Klotho: a novel approach for preserving beta-cells in type 2 diabetes. Diabetes. 2015;64:1444–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4375073</ArticleId>
            <ArticleId IdType="pubmed">25377875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mencke R, Hillebrands JL, consortium N. The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology. Ageing research reviews. 2017;35:124–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27693241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, et al.
Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 2008;27:7094–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18762812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Sun Z. Molecular basis of Klotho: from gene to function in aging. Endocr Rev. 2015;36:174–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4399270</ArticleId>
            <ArticleId IdType="pubmed">25695404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev. 2009;8:43–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2637560</ArticleId>
            <ArticleId IdType="pubmed">19022406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, et al.
Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2–4. Clinical journal of the American Society of Nephrology : CJASN. 2014;9:1049–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4046724</ArticleId>
            <ArticleId IdType="pubmed">24677555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C, et al.
Plasma klotho and cardiovascular disease in adults. Journal of the American Geriatrics Society. 2011;59:1596–601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3486641</ArticleId>
            <ArticleId IdType="pubmed">21883107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen K, Zhang B, Sun Z. MicroRNA 379 Regulates Klotho Deficiency-Induced Cardiomyocyte Apoptosis Via Repression of Smurf1. Hypertension. 2021;78:342–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8285029</ArticleId>
            <ArticleId IdType="pubmed">34120450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y, Sun Z. Klotho deficiency-induced arterial calcification involves osteoblastic transition of VSMCs and activation of BMP signaling. J Cell Physiol. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Kanbay M, Demiray A, Afsar B, Covic A, Tapoi L, Ureche C, et al.
Role of Klotho in the Development of Essential Hypertension. Hypertension. 2021;77:740–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33423524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv J, Chen J, Wang M, Yan F. Klotho alleviates indoxyl sulfate-induced heart failure and kidney damage by promoting M2 macrophage polarization. Aging (Albany NY). 2020;12:9139–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7288965</ArticleId>
            <ArticleId IdType="pubmed">32464602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J, Cha SK, An SW, Kuro OM, Birnbaumer L, Huang CL. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun. 2012;3:1238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3526952</ArticleId>
            <ArticleId IdType="pubmed">23212367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Wang S, Sun Z. Kidney-Specific Klotho Gene Deletion Causes Aortic Aneurysm via Hyperphosphatemia. Hypertension. 2021;78:308–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8285030</ArticleId>
            <ArticleId IdType="pubmed">34176284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension. 2009;54:810–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2814175</ArticleId>
            <ArticleId IdType="pubmed">19635988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao D, Wang S, Lin Y, Sun Z. In vivo AAV delivery of glutathione reductase gene attenuates anti-aging gene klotho deficiency-induced kidney damage. Redox Biol. 2020;37:101692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7476318</ArticleId>
            <ArticleId IdType="pubmed">32863229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y, Sun Z. Antiaging Gene Klotho Attenuates Pancreatic β-Cell Apoptosis in Type 1 Diabetes. Diabetes. 2015;64:4298–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4657580</ArticleId>
            <ArticleId IdType="pubmed">26340932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y, Sun Z. In vivo pancreatic β-cell-specific expression of antiaging gene Klotho: a novel approach for preserving β-cells in type 2 diabetes. Diabetes. 2015;64:1444–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4375073</ArticleId>
            <ArticleId IdType="pubmed">25377875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Fan J, Wang S, Sun Z. Secreted Klotho Attenuates Inflammation-Associated Aortic Valve Fibrosis in Senescence-Accelerated Mice P1. Hypertension. 2018;71:877–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5897144</ArticleId>
            <ArticleId IdType="pubmed">29581213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng R, Ullah M, Chen K, Ali Q, Lin Y, Sun Z. Stem cell-derived extracellular vesicles mitigate ageing-associated arterial stiffness and hypertension. J Extracell Vesicles. 2020;9:1783869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7480600</ArticleId>
            <ArticleId IdType="pubmed">32939234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Chen K, Lei H, Sun Z. Klotho gene deficiency causes salt-sensitive hypertension via monocyte chemotactic protein-1/CC chemokine receptor 2-mediated inflammation. J Am Soc Nephrol. 2015;26:121–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4279730</ArticleId>
            <ArticleId IdType="pubmed">24904083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Chen K, Wang Y, Schuman M, Lei H, Sun Z. Antiaging Gene Klotho Regulates Adrenal CYP11B2 Expression and Aldosterone Synthesis. J Am Soc Nephrol. 2016;27:1765–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4884100</ArticleId>
            <ArticleId IdType="pubmed">26471128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Lin Y, Sun Z. Deficiency in the anti-aging gene Klotho promotes aortic valve fibrosis through AMPKα-mediated activation of RUNX2. Aging Cell. 2016;15:853–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5013020</ArticleId>
            <ArticleId IdType="pubmed">27242197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X, Sun Z. Epigenetic Regulation of KL (Klotho) via H3K27me3 (Histone 3 Lysine [K] 27 Trimethylation) in Renal Tubule Cells. Hypertension. 2020;75:1233–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7805580</ArticleId>
            <ArticleId IdType="pubmed">32223380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ullah M, Sun Z. Klotho Deficiency Accelerates Stem Cells Aging by Impairing Telomerase Activity. J Gerontol A Biol Sci Med Sci. 2019;74:1396–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6696722</ArticleId>
            <ArticleId IdType="pubmed">30452555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao D, Zuo Z, Tian J, Ali Q, Lin Y, Lei H, et al.
Activation of SIRT1 Attenuates Klotho Deficiency-Induced Arterial Stiffness and Hypertension by Enhancing AMP-Activated Protein Kinase Activity. Hypertension. 2016;68:1191–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5063709</ArticleId>
            <ArticleId IdType="pubmed">27620389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi L, Wu Y, Lv DL, Feng L. Scutellarein selectively targets multiple myeloma cells by increasing mitochondrial superoxide production and activating intrinsic apoptosis pathway. Biomed Pharmacother. 2019;109:2109–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30551468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, Hill K, et al.
Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. Journal of the American Society of Nephrology : JASN. 2015;26:1290–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4446876</ArticleId>
            <ArticleId IdType="pubmed">25326585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen K, Sun Z. Estrogen inhibits renal Na-Pi Co-transporters and improves klotho deficiency-induced acute heart failure. Redox Biol. 2021;47:102173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8577443</ArticleId>
            <ArticleId IdType="pubmed">34678656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Zhu LJ, Waaga-Gasser AM, Ding Y, Cao M, Jadhav SJ, et al.
The axis of local cardiac endogenous Klotho-TGF-β1-Wnt signaling mediates cardiac fibrosis in human. J Mol Cell Cardiol. 2019;136:113–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31520610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J, Yoon J, An SW, Kuro-o M, Huang CL. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. Journal of the American Society of Nephrology : JASN. 2015;26:1150–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4413766</ArticleId>
            <ArticleId IdType="pubmed">25475745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang K, Wang C, Nie L, Zhao X, Gu J, Guan X, et al.
Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy. J Am Soc Nephrol. 2015;26:2434–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4587686</ArticleId>
            <ArticleId IdType="pubmed">25804281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcais C, Maucort-Boulch D, Drai J, Dantony E, Carlier MC, Blond E, et al.
Circulating Klotho Associates With Cardiovascular Morbidity and Mortality During Hemodialysis. The Journal of clinical endocrinology and metabolism. 2017;102:3154–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28402487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, et al.
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396:474–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9853756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Wang Q, Sun Z. Normal IgG downregulates the intracellular superoxide level and attenuates migration and permeability in human aortic endothelial cells isolated from a hypertensive patient. Hypertension. 2012;60:818–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3421057</ArticleId>
            <ArticleId IdType="pubmed">22777940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georget M, Mateo P, Vandecasteele G, Jurevicius J, Lipskaia L, Defer N, et al.
Augmentation of cardiac contractility with no change in L-type Ca2+ current in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J. 2002;16:1636–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12206999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park WJ, Oh JG. SERCA2a: a prime target for modulation of cardiac contractility during heart failure. BMB Rep. 2013;46:237–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4133892</ArticleId>
            <ArticleId IdType="pubmed">23710633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai NC, Roth DM, Gao MH, Tang T, Dalton N, Lai YY, et al.
Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation. 2004;110:330–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15249510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammond HK, Penny WF, Traverse JH, Henry TD, Watkins MW, Yancy CW, et al.
Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2016;1:163–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5535743</ArticleId>
            <ArticleId IdType="pubmed">27437887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan L, Vatner SF, Vatner DE. Disruption of type 5 adenylyl cyclase prevents β-adrenergic receptor cardiomyopathy: a novel approach to β-adrenergic receptor blockade. Am J Physiol Heart Circ Physiol. 2014;307:H1521–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4233298</ArticleId>
            <ArticleId IdType="pubmed">25193472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao MH, Lai NC, Giamouridis D, Kim YC, Guo T, Hammond HK. Cardiac-directed expression of a catalytically inactive adenylyl cyclase 6 protects the heart from sustained β-adrenergic stimulation. PLoS One. 2017;12:e0181282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5540275</ArticleId>
            <ArticleId IdType="pubmed">28767701</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
